CEO INTERVIEW: Stephan Titze, General Manager of Syngenta China. Stephan Titze is General Manager of agribusiness company Syngenta China. Previously, he was General Manager of Syngenta Indonesia, and held several positions within the company, and with UK-based Zeneca.

Those of who took note of Zacks senior biotech analyst Jason Napodano, CFA's upgrade to a Buy recommendation for Sciele Pharmaceuticals (SCRX) early this year will be happy to know the company has just been sold to Shionogi & Co., a Japanese firm, for $1.4 billion in cash. Shares of SCRX were up about 60% as of today's opening.  Price appreciation has skyrocketed to around $30.58 per share.

It helps that this comes of a day with positive momentum for the stock market as the price of oil has again come down.  Nevertheless, congratulations to all who took Jason's advice, when shares were trading at under $19 per share he said, "We believe the current share price represents an attractive entry point for long-term investors and we rate the stock a Buy."

We await an updated report on SCRX in the days to come.  But the buyout also reaffirms the industry

...

Those of who took note of Zacks senior biotech analyst Jason Napodano, CFA's upgrade to a Buy recommendation for Sciele Pharmaceuticals (SCRX) early this year will be happy to know the company has just been sold to Shionogi & Co., a Japanese firm, for $1.4 billion in cash. Shares of SCRX were up about 60% as of today's opening.  Price appreciation has skyrocketed to around $30.58 per share.

It helps that this comes of a day with positive momentum for the stock market as the price of oil has again come down.  Nevertheless, congratulations to all who took Jason's advice, when shares were trading at under $19 per share he said, "We believe the current share price represents an attractive entry point for long-term investors and we rate the stock a Buy."

We await an updated report on SCRX in the days to come.  But the buyout also reaffirms the industry

...

The entire interview with Cliff Goldstein of AMIDEX is part of our new subscription newsletter, Israel Opportunity Investor. You can find out more about the product and the opportunities we cover at www.israelnewsletter.com.

Can you tell us how AMIDEX got started?
Cliff Goldstein: I’m a lawyer by trade. In 1998 I saw some really compelling advances being made by Israeli technology companies. I decided to go to brokerage firms to see if I could find a way to invest in this ingenuity. I was specifically looking for a mutual fund that invested in Israeli companies. There wasn’t anything out there. After speaking directly to brokers, it was also clear to me that brokers themselves weren’t really knowledgeable about what was occurring on the ground in Israel. I then went to Israeli

…